Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
2
|
pubmed:dateCreated |
1995-7-20
|
pubmed:abstractText |
Nuclear magnetic resonance (NMR) imaging shows promise in the measurement of human cerebral blood flow (CBF) in that nonradioactive indicators may be used. Our earlier investigations with trifluoromethane (FC-23) gas have shown that this compound can be used to safely and effectively measure CBF in anesthetized animal models. In this Phase I dose-escalation study we set out to determine the maximal tolerated concentration (MTC) of FC-23 in normal healthy male volunteers and to assess its feasibility as an NMR indicator. Five subjects were exposed in a blinded fashion to escalating concentrations of FC-23 between 10% and 60%, randomly interleaved with exposures to both room air and 40% nitrous oxide. On each study day, the subjects breathed the test gas for eight pulses of 3 min each with 2-min clearance periods between the pulses. The subjects underwent intensive physiologic and neurobehavioral monitoring throughout the study period. The first subject experienced an anesthetic response to 60% FC-23, and the second subject experienced "discomfort" and requested discontinuation at the initiation of 40% FC-23. The MTC was subsequently determined to be 30% FC-23 (all subjects tolerated the gas), although a small (37.6 vs. 40.5) but statistically significant retention of carbon dioxide was found (p = .003). When one subject received 30% FC-23 during an NMR imaging study, a pronounced anesthetic effect with intolerable hyperacusis was demonstrated. Human studies of FC-23 have been discontinued in our laboratory.
|
pubmed:grant | |
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Jun
|
pubmed:issn |
0098-4108
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
45
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
221-9
|
pubmed:dateRevised |
2007-11-14
|
pubmed:meshHeading |
pubmed-meshheading:7783254-Administration, Inhalation,
pubmed-meshheading:7783254-Adolescent,
pubmed-meshheading:7783254-Adult,
pubmed-meshheading:7783254-Analysis of Variance,
pubmed-meshheading:7783254-Blood Chemical Analysis,
pubmed-meshheading:7783254-Blood Pressure,
pubmed-meshheading:7783254-Carbon Dioxide,
pubmed-meshheading:7783254-Cerebrovascular Circulation,
pubmed-meshheading:7783254-Chlorofluorocarbons, Methane,
pubmed-meshheading:7783254-Dose-Response Relationship, Drug,
pubmed-meshheading:7783254-Double-Blind Method,
pubmed-meshheading:7783254-Heart Rate,
pubmed-meshheading:7783254-Humans,
pubmed-meshheading:7783254-Magnetic Resonance Spectroscopy,
pubmed-meshheading:7783254-Male,
pubmed-meshheading:7783254-Oxygen,
pubmed-meshheading:7783254-Respiration
|
pubmed:year |
1995
|
pubmed:articleTitle |
Neurobehavioral and physiologic effects of trifluoromethane in humans.
|
pubmed:affiliation |
College of Pharmacy and Allied Health Professions, Wayne State University, Detroit, MI 48202, USA.
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, U.S. Gov't, P.H.S.,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't
|